The Atlantic's on-site portrayal of the Enhanced Games captures the visual spectacle of athletes transformed by 37 substances under clinical supervision, yet it underplays how this venture-backed spectacle directly challenges the World Anti-Doping Agency's selective enforcement model exposed in the 2016 Russian scandal. Peter Thiel's $300 million infusion through 1789 Capital, explicitly tied to narratives of American exceptionalism, reframes doping not as cheating but as entrepreneurial optimization, echoing earlier biohacking experiments like those documented in Wired's coverage of nootropics and growth hormone use among Silicon Valley executives. What the original piece misses is the economic coercion at play: athletes like Andrii Govorov cite training costs and geopolitical instability post-invasion as drivers, a pattern repeated in Lance Armstrong-era cycling where systemic underpayment pushed competitors toward enhancements. Fairness questions arise immediately when protocols remain trade secrets while promising $1 million prizes, potentially widening gaps between funded biohackers and clean athletes reliant on outdated natural limits. Health implications extend beyond reported mood swings to untracked long-term risks, as seen in historical cases where beta-blockers and testosterone combinations led to cardiovascular strain without transparent longitudinal data. This event signals a broader cultural pivot where performance enhancement migrates from underground to venture-funded spectacle, bypassing IOC governance entirely.